Related Experiment Video
Updated: May 3, 2026
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
A novel stroma-dependent leukemia cell line from a patient with mixed-phenotype acute leukemia with Ph chromosome and
Shoko Ishii1, Yasuhiro Arakawa2,3, Hiroto Ishii1
1Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Abstract:
Mixed phenotype acute leukemia (MPAL) is a rare and aggressive form of leukemia with a poor prognosis and no established treatment. In this study, we established a novel leukemic cell line, JMPAL-1, from a specimen of a 69-year-old patient with Philadelphia chromosome-positive MPAL. Flow cytometry showed that JMPAL-1 expresses B-cell markers but not myeloperoxidase. A genomic analysis of JMPAL-1 cells revealed the BCR::ABL1 fusion gene, missense mutation in PAX5, homozygous deletion of CDKN2A/CDKN2B, and BRAF amplification. This cell line was stroma-dependent in proliferation and required co-culturing with mouse bone marrow-derived mesenchymal cells (9-15C). Knowing the differences between JMPAL-1 and patient leukemia cells may improve understanding of the in vivo versus in vitro behavior of leukemia, clonal selection, and transformation. The stroma-dependent growth pattern of JMPAL-1 also provides a unique platform to study tumor-stromal interactions and their role in leukemic cell survival and drug resistance. Our study highlights the importance of establishing preclinical models such as JMPAL-1 and performing detailed cytogenetic analysis to develop targeted therapies in line with the pathogenesis of the disease.
Insights
Researchers developed JMPAL-1, a novel cell line for studying mixed phenotype acute leukemia (MPAL). This stroma-dependent model aids research into MPAL
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Mixed phenotype acute leukemia (MPAL) is rare, aggressive, and lacks established treatments.
- Understanding MPAL pathogenesis is crucial for developing effective therapies.
Purpose of the Study:
- Establish a novel preclinical model for Philadelphia chromosome-positive MPAL.
- Characterize the genetic and cellular properties of the new MPAL cell line.
- Investigate stroma-leukemia interactions in MPAL.
Main Methods:
- Established JMPAL-1 cell line from a patient with Philadelphia chromosome-positive MPAL.
- Utilized flow cytometry for immunophenotypic analysis.
- Performed genomic analysis including fusion gene detection, mutation analysis, and copy number variation.
- Assessed stroma-dependent proliferation through co-culturing with mesenchymal cells.
Main Results:
- JMPAL-1 expresses B-cell markers and lacks myeloperoxidase.
- Genomic analysis revealed BCR::ABL1 fusion, PAX5 mutation, CDKN2A/CDKN2B deletion, and BRAF amplification.
- JMPAL-1 exhibits stroma-dependent proliferation, requiring co-culture with mesenchymal cells.
Conclusions:
- The JMPAL-1 cell line serves as a valuable preclinical model for MPAL research.
- This model facilitates the study of leukemia behavior, clonal selection, and transformation.
- JMPAL-1 enables investigation of tumor-stromal interactions and their role in drug resistance.
More Related Videos
12:58Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...